Accessing Truqap (Capivasertib) in India
for Advanced Breast Cancer
Patient Background
52-year-old patient from Bhopal was diagnosed with advanced breast cancer showing progression after multiple standard therapies.
Clinical Recommendation
Her oncologist recommended Truqap(capivasertib) based on molecular signaling pathway involvement and international treatment data.
Regulatory & Access Challenges
- Regulatory approvals
- Reliable international sourcing
- Strict compliance with import norms
Timeline
MitoGENE managed:
- End-to-end regulatory documentation
- CDSCO Form 12B approvals
- Import permits, customs clearance, and logistics
Outcomes
Truqap(capivasertib) was successfully imported and administered as per the treatment plan. The patient tolerated therapy well and continued treatment under close medical supervision.
Conclusion
This case demonstrates how precision oncology therapies can reach Indian patients through compliant NPP frameworks when supported by experienced partners like MitoGENE.
Disclaimer
MitoGENE facilitates patient-specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B. The products mentioned are not approved for commercial sale in India. Access is strictly for personal use under physician supervision. Information provided on this website is sourced from publicly available references, and MitoGENE is not responsible for its completeness or accuracy. MitoGENE does not promote or sell any specific product and does not replace advice from qualified healthcare professionals.